Clinical outcome in lung cancer with a second malignancy
نویسندگان
چکیده
منابع مشابه
Clinical outcome in lung cancer with a second malignancy
The aim of the study was to determine the clinical outcome of lung cancer patients with a secondary malignancy according to the time sequence between the lung cancer and the secondary malignancy.Retrospective review of all lung cancer patients with any secondary cancer treated from June 2004 to July 2012. The survival of patients with a secondary malignancy was compared to those patients withou...
متن کاملCharacteristics and outcome of patients with second primary lung cancer.
Patients with lung cancer are at risk of developing a second primary lung cancer (SPLC). However, the characteristics of patients at risk remain largely speculative. We reviewed 2816 lung cancer patients from our institution for the occurrence of SPLC. Any SPLC was categorised as synchronous when diagnosed within 2 years of the first primary lung cancer (FPLC) and after direct histological comp...
متن کاملBreast cancer followed by second malignancy.
Among 232 cases of operable breast cancer treated by the 2nd Department of Surgery, Hiroshima University School of Medicine, between 1963 and 1982, 7 cases (3. 0%) were followed by a second primary malignancy. Eighty six percent of the second primary malignancies were found in digestive systems. The incidence of a second primary malignancy was 6. 1%* (5/82) in the irradiated group and 1. 3%* (2...
متن کاملAssociation of nonmelanoma skin cancer with second malignancy.
BACKGROUND Heightened risks of second cancers have been reported in patients with nonmelanoma cancer of the skin (NMSC), but this association has not been studied in a large, ethnically diverse, multigeographic population. METHODS This cross-sectional study assessed the association of NMSC with another malignancy in the Women's Health Initiative Observational Study, a study that was conducted...
متن کاملOutcome of small cell lung cancer (SCLC) patients with brain metastases in a routine clinical setting
BACKGROUND Small cell lung cancer (SCLC) represents approximately 13 to 18% of all lung cancers. It is the most aggressive among lung cancers, mostly presented at an advanced stage, with median survival rates of 10 to12 months in patients treated with standard chemotherapy and radiotherapy. In approximately 15-20% of patients brain metastases are present already at the time of primary diagnosis...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Medicine
سال: 2016
ISSN: 0025-7974
DOI: 10.1097/md.0000000000005203